Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of ALS-008176 in hospitalized infants and children with RSV infection
2016-001641-79Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing ALS-008176 regimen with Placebo (2 arms). Primary endpoint: RSV RNA viral load AUC from baseline until Day 7. Started Apr 2019; status: terminated.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2016-001641-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001641-79.